-+ 0.00%
-+ 0.00%
-+ 0.00%

Why Biohaven stock is up today

Barchart·11/19/2026 10:18:10
Listen to the news

BHVN Cover Image

What happened?

Shares of Biohaven jumped 10% in the morning session after the company announced clinical data from the ongoing Phase 1 study of BHV-1530, its potential first-in-class FGFR3-directed antibody-drug conjugate (ADC) with a topoisomerase I (TopoIx) payload. 

In a company press release, Biohaven stated that the data were presented by Gerald S. Falchook, M.D., Director of Sarah Cannon Research Institute at HCA HealthONE, in an oral presentation during Plenary Session 3 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain. The release also noted that as of the October 19, 2026 data cutoff, 30 patients had received BHV-1530 monotherapy every three weeks at doses from 1.0 to 12.0 mg/kg, and dose escalation is ongoing.

The shares were trading at $13.88, up 7.6% from the previous close.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.